We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · April 10, 2021

Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease

JAMA Neurology

 

Additional Info

JAMA Neurology
Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial
JAMA Neurol 2021 Mar 01;78(3)293-301, R Sperling, D Henley, PS Aisen, R Raman, MC Donohue, K Ernstrom, MS Rafii, J Streffer, Y Shi, K Karcher, N Raghavan, Y Tymofyeyev, J Bogert, HR Brashear, G Novak, J Thipphawong, ZS Saad, H Kolb, H Rofael, P Sanga, G Romano

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading